NeoGenomics Inc (NEO) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Total Cash From Operating Activities Chart for NeoGenomics Inc
NeoGenomics Inc (NEO) operating cash flow for FY2025 was USD 5.2M, a -25.5% change from FY2024. NeoGenomics Inc's operating cash flow moved from USD -177.1K in 2000 to USD 5.2M in 2025 over 25 years. Operating cash flow compound annual growth rate: 5-year CAGR of 29.1%, 10-year CAGR of -2.0%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $2.14B
- Implied Share Price
- $16.65
- Enterprise Value
- $2.66B
- Revenue (TTM)
- $766.29M
- EBITDA
- $24.32M
- Profit Margin
- -6.77%
- Trailing P/E
- —
- Forward P/E
- 222.22
- Price/Book (MRQ)
- 3.00
- Price/Sales (TTM)
- 2.83
- EV/EBITDA
- 197.32
- EV/Revenue
- 3.47
- Dividend Yield
- —
- Book Value
- $6.14
- Free Cash Flow (FY2025)
- -$21.78M
- Free Cash Flow Yield
- -1.02%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.